Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06150365

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Refractory Solid Tumors Relapsed Solid Tumors

Updated 4 times since 2023 Last updated: Mar 24, 2025 Started: Nov 7, 2023 Primary completion: Dec 1, 2026 Completion: Dec 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06150365, this EARLY_PHASE1 trial focuses on Refractory Solid Tumors and Relapsed Solid Tumors and remains actively recruiting participants. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Sep 2024 — Apr 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Dec 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China